ReviewJournal of the American Heart Association2022
Circulating Biomarkers in Hypertrophic Cardiomyopathy.
Review in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study.Journal of the American Heart Association · 2026Trial
- Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.European heart journal · 2024Trial
- Investigation of plasma-derived extracellular vesicles in hypertrophic cardiomyopathy patients.iScience · 2026Article
- Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.Cardiovascular drugs and therapy · 2026Review
- A pragmatic clinical risk score for adverse outcomes in hypertrophic cardiomyopathy using routine laboratory and bedside variables.BMC cardiovascular disorders · 2026Article
- Biobank-Scale Plasma Proteomics Identifies Novel Biomarkers in Hypertrophic Cardiomyopathy.Circulation. Genomic and precision medicine · 2026Article
- Construction and verification of a diagnostic nomogram for heart failure in hypertrophic cardiomyopathy based on conventional clinical indicators: a case-control study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Genetic determinants of heart failure susceptibility and response in the collaborative cross mouse population.Genetics · 2026Article
- Machine learning-based risk stratification identifies heart failure with preserved ejection fraction as an independent predictor of adverse outcomes in hypertrophic cardiomyopathy.Scientific reports · 2026Article
- Biomarkers as Clinical Endpoints in Hypertrophic Cardiomyopathy Clinical Trials.Current heart failure reports · 2026Review
- Evaluation of artificial intelligence-based electrocardiogram analysis tools in patients with hypertrophic cardiomyopathy.European heart journal. Digital health · 2026Article
- Diabetic Atrial Cardiomyopathy: Pathogenesis, Diagnosis, Management, AI-Driven Diagnosis, and Risk Prediction.Journal of diabetes research · 2026Review
- Impaired left ventricular global longitudinal strain is associated with diastolic dysfunction in obstructive hypertrophic cardiomyopathy.BMC medical imaging · 2025Article
- Endothelial-specific genes TMTC1, RPS6KA2, and F8 are downregulated in hypertrophic cardiomyopathy.European journal of medical research · 2025Article
- The Diagnostic Significance of Circulating Eicosanoid in Patients with Hypertrophic Cardiomyopathy.Journal of cardiovascular translational research · 2025Article
- Anabolic-Androgenic Steroids Induced Cardiomyopathy: A Narrative Review of the Literature.Biomedicines · 2025Review
- Altered β-Adrenergic System, Cardiac Dysfunction, and Lethal Arrhythmia in a Rat Model of Metabolic Syndrome.International journal of molecular sciences · 2025Article
- KLK8: charting new territories in left ventricular hypertrophy biomarker research.Biomarkers in medicine · 2025Article
- Clinical and Echocardiographic Particularities of Hypertrophic Cardiomyopathy in a Brazilian Population and its Prognostic Impact.Arquivos brasileiros de cardiologia · 2025Article
- Integrative multi-omics identifies MEIS3 as a diagnostic biomarker and immune modulator in hypertrophic cardiomyopathy.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.